Compounds and methods of using the same for treating conditions alleviated by SKI complex inhibition, viral replication inhibition, or interferon signaling inducement are provided.

The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.

The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.

A pyrimidinone compound represented by formula (1): ##STR00001##
[wherein: A.sup.1 represents a nitrogen atom or a CR.sup.4; A.sup.2 represents a nitrogen atom and A.sup.3 represents a CR.sup.3b, or A.sup.2 represents a CR.sup.3a and A.sup.3 represents a nitrogen atom; Q represents an oxygen atom or a sulfur atom; G represents a C2-C10 chain hydrocarbon group having one or more halogen atoms, etc.; R.sup.1 represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms; R.sup.2 represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, etc.; R.sup.4 represents a hydrogen atom, etc.; R.sup.3, R.sup.3a, and R.sup.3b represent independently of each other a hydrogen atom, etc.; n represents 0, 1, or 2; and p represents 0, 1, 2, or 3]
has an excellent efficacy for controlling harmful arthropods.

The invention relates to a compound of Formulae I and/or II: ##STR00001##
and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof; X is selected from Se, NOH, NH, NO.sub.2, CN, NCN, NO, O or S, and the remaining substituents are described herein; and a composition thereof. The invention also relates to a method of administration thereof; and use thereof to treat HIV.

The invention relates to a compound of Formulae I and/or II: ##STR00001##
and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof; X is selected from Se, NOH, NH, NO.sub.2, CN, NCN, NO, O or S, and the remaining substituents are described herein; and a composition thereof. The invention also relates to a method of administration thereof; and use thereof to treat HIV.

The present invention relates to a benzamide derivative compound, a method for preparing the same, and a pharmaceutical composition for treating or preventing an inflammatory disease containing the same as an active ingredient. The benzamide derivative compound according to the present invention inhibits the expression of PDE4 and regulates the expression of an inflammatory disease-related substance such as IL-4 (interleukin-4), IL-5 (interleukin-4), IFN- (interferon-), IL-17 (interluekin-17), IgE (immunoglobulin E), and TNF- (tumor necrosis factor-), and thus may be utilized as a pharmaceutical composition for treating or preventing an inflammatory disease.

The present invention relates to a benzamide derivative compound, a method for preparing the same, and a pharmaceutical composition for treating or preventing an inflammatory disease containing the same as an active ingredient. The benzamide derivative compound according to the present invention inhibits the expression of PDE4 and regulates the expression of an inflammatory disease-related substance such as IL-4 (interleukin-4), IL-5 (interleukin-4), IFN- (interferon-), IL-17 (interluekin-17), IgE (immunoglobulin E), and TNF- (tumor necrosis factor-), and thus may be utilized as a pharmaceutical composition for treating or preventing an inflammatory disease.

Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)). ##STR00001##